How do peptides work?
How do peptides work? These mechanism articles are the how behind the what. If you want to understand what a GLP-1 dual agonist actually does after injection, why a growth hormone peptide works with your pituitary instead of around it, or which receptor a molecule binds — this is that shelf.
Written to be understood like you're fifteen, sourced from the primary literature, and honest wherever the mechanism is still a hypothesis rather than settled science.
148 articles on this topic
-
Tirzepatide for Type 2 Diabetes: Trial Results
Across the SURPASS trials, adults assigned to tirzepatide had average HbA1c reductions of roughly 1.9 to 2.4 percentage points over 40 to 52 weeks. The right comparison depends on a person's existing diabetes treatment and clinical risks.
-
Thymosin Beta-4: What It Is and How TB-500 Relates
Thymosin beta-4 is a 43-amino-acid protein that helps cells manage actin. TB-500 is a seven-amino-acid synthetic fragment, so research on the parent molecule cannot simply be assigned to the product.
-
CJC-1295 No DAC: What the Label Actually Means
CJC-1295 no DAC is label shorthand for modified GRF 1-29, a short-acting GHRH analog without the albumin-binding feature that makes the DAC form last for days.
-
What Happens When You Stop Taking Semaglutide
Appetite commonly returns as semaglutide clears, and some weight regain is likely. Trials show why stopping is better treated as a long-term care decision than as a test of willpower.
-
What Is Kisspeptin-10? The Decapeptide Explained
Kisspeptin-10 is the last ten amino acids of the full 54-residue peptide — the shortest fragment that still switches on the receptor. It also clears from human blood in about four minutes, which shapes everything about how it is given.
-
How Long Does Tirzepatide Stay in Your System?
Tirzepatide usually takes about 25–30 days to fall to a small fraction of its starting level after the last dose. Its five-to-six-day half-life explains that estimate, but side effects and clinical effects do not end on one exact day.
-
Does Sermorelin Work? What Human Studies Show
Small human studies show that sermorelin can increase growth hormone output, but IGF-1 and body-composition results are inconsistent. Whether it is working should be judged with labs and a prescriber, not a feeling or a promised calendar.
-
Tesamorelin vs Sermorelin: What Actually Differs
Both are growth-hormone-releasing hormone analogues and they are not interchangeable: one is a 44-amino-acid molecule with a current US approval, the other a 29-amino-acid fragment whose branded product left the market in 2008.
-
How Long Does Semaglutide Stay in Your System?
Injectable semaglutide has an elimination half-life of about one week and can remain in circulation for roughly five to seven weeks after the last dose. Its effects fade on a curve, not at a single cutoff.
-
Is Tirzepatide a Peptide? A Clear Answer
Yes. Tirzepatide is a 39-amino-acid synthetic peptide, and it is also a dual GIP/GLP-1 receptor agonist. Those labels describe its structure and its action, respectively.
-
DSIP Dosage: What the Human Studies Used
There is no standard clinical dose for delta sleep-inducing peptide. The small human studies used intravenous infusions under observation, not a validated at-home schedule.
-
How Does Semaglutide Work? Four Effects Explained
Semaglutide activates one receptor but produces coordinated signals in the pancreas, stomach and brain. Its engineered C18 side chain keeps those signals available for about a week.
-
How Does Tirzepatide Work? The Dual Mechanism
Tirzepatide activates two nutrient-sensitive hormone receptors, not one. The result is a linked set of effects on insulin, glucagon, stomach emptying and the signals that shape hunger and fullness.
-
Sermorelin Benefits: What the Trials Found
In the best controlled study of GHRH in older adults, nocturnal growth hormone rose, IGF-1 climbed within two weeks, skin thickened — and lean body mass increased in men only. The specificity is the point.
-
Ipamorelin Benefits, Side Effects, Legal Status
Developed at Novo Nordisk in the late 1990s, ipamorelin is a five-amino-acid peptide that released growth hormone in animal studies without raising cortisol even at more than 200 times its effective dose.
-
Retatrutide and the Rise of the Triple Agonist
In its 48-week phase-2 obesity trial, retatrutide's highest dose produced an average 24.2% body-weight reduction — at publication, the largest average weight loss any obesity drug trial had reported.
-
Epitalon Benefits, Sorted by Evidence Tier
The most-cited animal experiment gave 54 mice per group monthly doses for life and found mean lifespan unchanged, maximum lifespan up 12.3%, and leukemia down six-fold.
-
Oxytocin Peptide Beyond the 'Love Hormone'
A 2025 meta-analysis pooling 20 effect estimates from 13 human studies found no overall effect of oxytocin on non-social executive function — one number that explains why this molecule's science reads nothing like its nickname.
-
The Thymulin Peptide Needs Zinc to Work
Thymulin is inert until a zinc ion binds it at a 1:1 molar ratio — and most published results in its literature come from mice, rats, or cell culture.
-
KPV Peptide and the Gut Inflammation Evidence
KPV is the C-terminal tripeptide of alpha-MSH, and in mice whose MC1R does not function, every animal in the KPV-treated group survived DSS colitis — a result that points away from melanocortin receptors entirely.
Page 7 of 8 · 148 articles